Chakrapani Ayurveda Clinic & Research Center – FDA 483, Feb 18, 2022
An FDA inspection of Chakrapani Ayurveda Clinic & Research Centre in Jaipur, India, revealed numerous deficiencies in their manufacturing and quality control processes for dietary supplements exported to the U.S. The firm failed to establish and follow written procedures for critical operations, including quality control, component and product specifications, and record-keeping. These issues indicate a severe lack of control over product quality, purity, and strength, raising concerns about the safety and compliance of their dietary supplements.
- Inspection date
- February 18, 2022
- Product type
- drugs
ID · c907f027-0d21-4e59-ab04-047c945cb334
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.